Article
Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma.
Nature communications - 21 Nov 2024
Wen Yalei, Wang Hui, Yang Xiao, Zhu Yingjie, Li Mei, Ma Xiuqing, Huang Lei, Wan Rui, Zhang Caishi, Li Shengrong, Jia Hongling, Guo Qin, Lu Xiaoyun, Li Zhengqiu, Shen Xiangchun, Zhang Qiushi, Si Lu, Yin Chengqian, Liu Tongzheng
Abstract excerpt
Activating mutations in NRAS account for 15-20% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K, which are the most prevalent NRAS mutations in melanoma. The genetic ablation or pharmacological inhibition of CK1δ markedly destabilizes NRAS mutants and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.